Who are Ibuprofen and Aprepitant's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibuprofen-and-aprepitant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ibuprofen and Aprepitant — Competitive Intelligence Brief

Ibuprofen and Aprepitant (Ibuprofen and Aprepitant) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + NK1 receptor antagonist combination. Area: Oncology; Pain Management.

phase 3 NSAID + NK1 receptor antagonist combination COX-1/COX-2 (ibuprofen); NK1 receptor (aprepitant) Oncology; Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ibuprofen and Aprepitant (Ibuprofen and Aprepitant) — Lahore Medical Research Center, LLP. This combination uses ibuprofen to reduce inflammation and pain via COX inhibition, while aprepitant blocks substance P receptors to prevent nausea and vomiting.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ibuprofen and Aprepitant TARGET	Ibuprofen and Aprepitant	Lahore Medical Research Center, LLP	phase 3	NSAID + NK1 receptor antagonist combination	COX-1/COX-2 (ibuprofen); NK1 receptor (aprepitant)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + NK1 receptor antagonist combination class)

Lahore Medical Research Center, LLP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ibuprofen and Aprepitant — Competitive Intelligence Brief. https://druglandscape.com/ci/ibuprofen-and-aprepitant. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab